Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Resident, Internal Medicine, Duke University School of Medicine 2008 - 2011
  • M.D., University of North Dakota, School of Medicine and Health Sciences 2008
• 

  Duke Appointment History

  • Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2018 - 2020
  • Medical Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2014 - 2017
• Research
• 

  Selected Grants

  • A Phase I Trial of Incorporating Natural Killer (K-NK) cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy awarded by Kiadis Pharma 2021 - 2026
  • A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia awarded by Imago BioSciences 2020 - 2025
  • Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis awarded by CTI Biopharma Corp. 2020 - 2025
  • Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ss) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis awarded by Actuate Therapeutics 2020 - 2025
  • COVID-19 Phase 3 Assess Efficacy of Ruxolitinib awarded by Incyte Corporation 2020 - 2025
  • BBI Ph1 TP-3654 and Ruxolitinb in patients with Intermediate and High Risk Myelofibrosis awarded by Sumitomo Dainippon Pharma Co. 2020 - 2025
  • A Phase 1b, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis awarded by Novartis Pharmaceuticals Corporation 2020 - 2024
  • Targeting beta-arrestins in myeloid malignancies awarded by Department of Defense 2020 - 2023
  • Targeting Beta-arrestins in myeloid malignancies awarded by  American Society of Hematology 2018 - 2020
  • An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination with Low-Dose Ruxolitinib or Itacitinib Alone following Ruxolitinib in Subjects with Myelofibrosis awarded by Incyte Corporation 2018 - 2020
  • B-arrestin2 and the disease course of chronic myeloid leukemia (CML) awarded by  American Society of Hematology 2014 - 2015
• 

  External Relationships

  • Blueprint Medicines
  • Celgene Corporation
  • Clinical Care Options
  • Novartis
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Gerds, Aaron T., Jason Gotlib, Prithviraj Bose, Michael W. Deininger, Andrew Dunbar, Amro Elshoury, Tracy I. George, et al. “Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 9 (September 2020): 1248–69. https://doi.org/10.6004/jnccn.2020.0042.
       Full Text  Link to Item
    • Paul, Barry, Yue Zhao, Gavin Loitsch, Daniel Feinberg, Parker Mathews, Ian Barak, Megan Dupuis, et al. “The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.” Cancer Med 9, no. 16 (August 2020): 5869–80. https://doi.org/10.1002/cam4.3265.
       Full Text  Link to Item
    • Gotlib, Jason, Aaron T. Gerds, Prithviraj Bose, Mariana C. Castells, Michael W. Deininger, Ivana Gojo, Krishna Gundabolu, et al. “Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 16, no. 12 (December 2018): 1500–1537. https://doi.org/10.6004/jnccn.2018.0088.
       Full Text  Link to Item
    • Rein, Lindsay A. M., Haeyoon Yang, and Nelson J. Chao. “Applications of Gene Editing Technologies to Cellular Therapies.” Biol Blood Marrow Transplant 24, no. 8 (August 2018): 1537–45. https://doi.org/10.1016/j.bbmt.2018.03.021.
       Full Text  Link to Item
    • Rein, Lindsay Am, James W. Wisler, Jihee Kim, Barbara Theriot, LiYin Huang, Trevor Price, Haeyoon Yang, et al. “β-Arrestin2 mediates progression of murine primary myelofibrosis.” Jci Insight 2, no. 24 (December 21, 2017). https://doi.org/10.1172/jci.insight.98094.
       Full Text  Link to Item
    • Mesa, Ruben A., Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, et al. “NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.” Journal of the National Comprehensive Cancer Network : Jnccn 15, no. 10 (October 2017): 1193–1207. https://doi.org/10.6004/jnccn.2017.0157.
       Full Text
    • Rein, Lindsay A. M., and David A. Rizzieri. “Clinical potential of elacytarabine in patients with acute myeloid leukemia.” Ther Adv Hematol 5, no. 6 (December 2014): 211–20. https://doi.org/10.1177/2040620714552615.
       Full Text  Link to Item
    • Rein, Lindsay A. M., and Nelson J. Chao. “WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.” Expert Opinion on Investigational Drugs 23, no. 3 (March 2014): 417–26. https://doi.org/10.1517/13543784.2014.889114.
       Full Text
    • Friedman, Daphne R., Lindsay A. Magura, Holly A. C. Warren, Jeremy D. Harrison, Louis F. Diehl, and J Brice Weinberg. “Statin use and need for therapy in chronic lymphocytic leukemia.” Leuk Lymphoma 51, no. 12 (December 2010): 2295–98. https://doi.org/10.3109/10428194.2010.520050.
       Full Text  Link to Item
    • Magura, Lindsay, Richelle Blanchard, Brian Hope, James R. Beal, Gary G. Schwartz, and Abe E. Sahmoun. “Hypercholesterolemia and prostate cancer: a hospital-based case-control study.” Cancer Causes Control 19, no. 10 (December 2008): 1259–66. https://doi.org/10.1007/s10552-008-9197-7.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.